AIM2 inflammasome: A potential therapeutic target in ischemic stroke

Clin Immunol. 2024 Feb:259:109881. doi: 10.1016/j.clim.2023.109881. Epub 2023 Dec 23.

Abstract

Ischemic stroke (IS) is a significant global public health issue with a high incidence, disability, and mortality rate. A robust inflammatory cascade with complex and wide-ranging mechanisms occurs following ischemic brain injury. Inflammasomes are multiprotein complexes in the cytoplasm that modulate the inflammatory response by releasing pro-inflammatory cytokines and inducing cellular pyroptosis. Among these inflammasomes, the Absent in Melanoma 2 (AIM2) inflammasome shows the ability to detect a wide range of pathogen DNAs, thereby triggering an inflammatory response. Recent studies have indicated that the aberrant expression of AIM2 inflammasome in various cells is closely associated with the pathological processes of ischemic brain injury. This paper summarizes the expression and regulatory role of AIM2 in CNS and peripheral immune cells and discusses current therapeutic approaches targeting AIM2 inflammasome. These findings aim to serve as a reference for future research in this field.

Keywords: AIM2 inflammasome; Inflammatory response; Ischemic stroke; Pyroptosis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain Injuries* / metabolism
  • DNA-Binding Proteins / metabolism
  • Humans
  • Inflammasomes / metabolism
  • Ischemic Stroke*
  • Melanoma*
  • Pyroptosis

Substances

  • Inflammasomes
  • AIM2 protein, human
  • DNA-Binding Proteins